申请人:Korea Research Institute of Chemical Technology
公开号:US07745439B2
公开(公告)日:2010-06-29
The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.
式(I)的创新茚类衍生物能够选择性调节过氧化物酶体增殖物激活受体(PPARs)的活性,不会引起不良副作用,因此,它们可用于调节PPARs调节的疾病的治疗和预防,例如代谢综合征,如糖尿病,肥胖症,动脉硬化,高血脂,高胰岛素血症和高血压,炎症性疾病,如骨质疏松,肝硬化和哮喘,以及癌症。